Oesophageal Doppler monitoring (ODM) device maker Deltex Medical Group plc (LON:DEMG) has received confirmation of monitor orders worth more than £200,000.
These orders had originally been expected to be signed off in 2016 but, as mentioned in Deltex’s January trading update, had slipped into the current year as a result of rescheduling of capital allocations in some hospitals.
- Read Deltex Medical sees probe revenue rise again
- Read the investment case for Deltex Medical
- Watch Deltex CEO Ewan Phillips talk about US growth opportunities
Deltex said the largest value sales contract is from the USA for six monitors from a seven hospital system in the company's Great Lakes sales territory.
The customer had originally planned to start implementation of ODM within its flagship hospital from April 2016 but, following delays in its procurement processes, has now decided to start implementation simultaneously in two additional hospitals.
The other major order is for 13 monitors from a consortium of NHS hospitals in the UK, comprising replacements for nine previously purchased monitors and four additional units.
"We are encouraged that we have been able to secure capital funding for our ODM monitors from major customers in both the USA and UK at a time of restricted capital budgets,” said Ewan Phillips, Deltex Medical’s chief executive.
“The US sales contract means we can now move forward with supporting implementation of ODM in one of the most prestigious of the US platform accounts we announced in 2016," he added.